Video: Regulatory Updates for Medical Device Manufacturers | Duration: 2828s | Summary: Regulatory Updates for Medical Device Manufacturers | Chapters: Regulatory Landscape Overview (219.31s), FDA Quality System Modernization (388.47s), Breakthrough Device Pathways (500.72s), UNAV Expansion Mandates (579.87s), PFAS Regulatory Landscape (652.21497s), Updated Audit Approach (772.095s), CDS Guidance Updates (911.055s), FDA-ISO Harmonization Implementation (1040.48s), Regulatory Updates Conclusion (1775.9299s)
Transcript for "Regulatory Updates for Medical Device Manufacturers": Welcome ladies and gentlemen. Thank you for joining me today. My name is Birchen Guilder and I'm the senior manager of the quality management consulting division here at NSF Prosystems PMBH, located at the Hamburg, Germany office, where we've been supporting medical device and in vitro diagnostic manufacturers with regulatory strategy and quality management for more than twenty years. I'm also a lead auditor with auditing experience for more than seven years now. And, you know, we've been supporting regular internal audits as well as mock audits, mock inspections to prepare for regular certification audits or inspections. I've also been conducting supply audits. And on top of that, I'm also involved in standardization work. Right now I'm serving on the Joint Advisory Group five of IEC's TC62, where we're focusing on sustainability and equity design for medical devices. So at NSF, strive to support you throughout the entire life cycle of your medical device, whether it is the initial regulatory strategy, the creation of submission documentation, the implementation of the entire quality management system, or supporting you together scientifically sound and objective clinical data, or whether it is supporting you in your post market activities or even the decommissioning of a production line, we are here to support you. Today's keynote really focuses on some of the most significant regulatory developments that have been happening or were announced in Q1 twenty twenty six up to this point, and that are potentially reshaping the golden medical device landscape in 2026. So what we'll cover today is first an overview of the Q1 twenty twenty six regulatory updates. Obviously not all of them, but the most significant ones. Then secondly, we will have a brief dive into how the FDA is harmonizing the 21CFR Part A20 with ISO's thirteen forty five twenty sixteen, which is a landmark shift toward global alignment. And thirdly, we will look at the proposed NDR, EU MDR and IVDR changes and what they may mean for your business. So by the end of this presentation, you should have a clear understanding of what's changing, why it matters, and what your organization should prioritize in the coming months. Let's begin. Let's have a look at the most significant updates that have happened or have been announced in Q1 twenty twenty six. So first and foremost, obviously, is the FDA's quality system modernization. So the transition from QSRs to QSRs represents more than just the name change. It reflects the modernization of FDA oversight, really. One of those changes involves the inspection process effective 02/02/2026. So the FDA has discontinued the quality system inspection technique, the Q SIFT. It now follows the updated inspection of medical device manufacturers compliance program. This aligns FDA inspection methodology more closely with international audit practices and what this really means for your organization, and we will get into more detail in the second part of this keynote, is that FDA inspectors will expect documentation and procedures aligned with ISO three thousand forty five twenty sixteen in addition to the specific national requirements in the QMSR. So it means quality manuals, design history files and device history records are being replaced with the ISO term medical device files. And yes, inspectors are now allowed more access to records such as management reviews or audit reports that are not a Q search where it's restricted to inspectors eyes only. And yeah, we'll get into more detail in a bit, but it's a brief overview of what's been changing with the FDA's modernization of the QMS R. So next is the breakthrough device pathways in December 2025. The Medical Device Coordination Group released guidance on breakthrough devices, both under the EU MDR and EU IVDR. So before we go any further, let's look at what breakthrough devices are. Breakthrough devices are defined as innovative medical devices or IVDs that represent significant technological advancements and provide substantial clinical benefits compared to existing alternatives. So the pilot program rolls out in Q2 twenty twenty six, provides expedited pathways for qualifying devices, as well as a formal assessment and certification process by notified bodies. The advantages for innovators really are that if your device qualifies, you may gain or you gain priority review and assessment, structured dialogue with notified bodies, and clearer, more predictable pathways to market. This is particularly relevant if you're developing novel diagnostics, advanced imaging devices, or next gen therapeutic delivery systems. Let's move on to the next news, which is the UNAV expansion. So one of the most significant administrative changes for EU operating companies is this UNAV expansion. From 05/28/2026, the expanded UDIMIT modules become mandatory. The modules that will be mandatory to use include the Actor registration, the UDI device registration, notified body certificates and market surveillance data. So this means that all economic operators must register. The unique device identification becomes mandatory for registration. Notified body certificates must be uploaded. Post market surveillance reports or PSURs become part of the Transparent ecosystem. However, be aware that market surveillance authorities can now access real time data on all devices in circulation. And gaps in media assignment or registration can trigger regulatory action and supply chain disruptions or quality issues become immediately visible. Another update is the PFAS scrutiny and regulatory clarity. I want to point out this one that I'm seeing create significant confusion in our consulting practice. The FDA issued a definitive position statement in August 2025 regarding the fluoropolymers, which are a class of PFAS including Teflon, which are currently used in medical devices to be safe and currently irreplaceable. That's the position that the FDA is holding, So there's no scientific basis for restricting their use in FDA regulated medical devices. However, and this is critical, there are state level regulations that are creating a more complex landscape. So the following states ban these materials actually, but currently with medical device exemptions, Connecticut effective July 2026 prohibits intentionally at a PFAS, but exempts the FDA regulated medical devices. For Colorado, New Mexico, Maine, Minnesota, there are similar bands with medical device and pharmaceutical exemptions. California also is likely to propose medical device exemptions by Q2 twenty twenty six. So what you need to do if PFAS is part of your medical device is that first of all, you need to understand which states your device are distributed to. Second of all, verify that your device is qualified for a medical device exemption and they should, if FDA regulation, if they are FDA regulated. Third of all, document your PFAS use and whether it's intentional and necessary. And last but not least, be prepared for potential state level inquiries or reporting requirements. Moving on to MD SAP audit approach is update version 10, which was published and was released on 02/02/2026. The major change certainly is that the audit model now aligns with FDA's QMSR and treats ISO 3,045 as backbone. Auditors verify ISO based processes and then check jurisdiction specific add ons rather than running ISO and FDA in parallel. So it also folds in the refreshed national references and topics like the preterm change control plans, the PCCPs for software and AI. Also, this version further updates the device marketing and authorization facility registration tasks and cleans up regional rules such as Anvisa's RDC seven fifty one twenty point two, the RDC eight thirty twenty twenty three, Australia's software references, ordinance 169 of Japan, plus it moves away from the legacy term critical supplier toward the ISO's risk based supplier involvement. What does this mean for you really is that you should update your internal checklists and map from QSR language to QMSR and ISO 35 and mirror the taskflow, harden your change control for PCCP certainly. So make sure that SOPs show how software changes stay within clear PCCP boundaries. Scrub your control documents and jurisdictional references to match the MVSA, PGA, MHLW references, and also confirm that US device listing records are audit ready. So bottom line is that version 10 is an alignment, not leniency. So it's mature integrated systems will glide through fragmented dual systems from our experience will feel more of a friction. And the last update that I want to talk about today is the clinical decision support software for which the FDA issued a revised final CDS guidance on 01/06/2026, and reissued one on 01/29/2026. So this '26 guidance oversees the '22 guidance, gives clearer tests for non device CDS and adds more examples. In this revision, the FDA clarifies the single recommendation flexibility. So the FDA signals enforcement discretion when a single clinically appropriate recommendation is provided if all other non device criteria are met and the use is not time critical. Furthermore, regarding signals, patterns and discrete data, there is a clear boundary between signals and patterns pushing them into divided territory, and discrete point in time medical information. The terminology medical information was also refined, so there's an explicit inclusion of typical clinical inputs such as demographics, symptoms, certain test results, discharge summaries and guidelines. There's also more transparency on data sources and quality remains essential, obviously, and they furthermore provide clarification on imaging and patient facing tools. Image analysis functions, state, device, consumer facing, online image interpretations are generally within FDA oversight. The FDA to this topic hosted a town hall specifically to explain the 2026 updates and reissue, and you can access them via the CDRH Learn website. So here's a quick overview of all the significant regulatory updates that I've just been talking about. Let's move on to the harmonization of the FDA's quality system regulation 21 CFR Part A20 with ISO twenty four thousand five hundred twenty sixteen and what it really changes. To understand why FDA's harmonization with the ISO is so significant, we need a bit of context. For decades, the FDA's quality system regulation and the ISO 3,045 were parallel, but they were distinct frameworks. Both addressed quality management, but with different terminology, emphasis and structural approaches. The challenge for manufacturers really was that companies operating globally had to maintain, well, maybe not dual documentation systems, but certainly had to invent their own form of an integrated management system and find the gaps between the ISO and the FDA's 21 CFR Part A20. Different terminology also meant different training requirements. Compliance teams had to justify how the same procedure met both frameworks, audits by FDA and auditors to ISO 3,085 could reach different conclusions, And with the final rule dated 01/31/2024, the FDA decided that rather than continue this fragmentation, it would align 21 CFR per day 20 with the ISO. So this brings The US into alignment with Canada, Europe, Australia, Japan, and most other major medical device markets. So the observed timeline is that we had the final rule issued in 01/31/2024. We had a transition period from 02/02/2024 through 02/01/2026. Now we have the full implementation since 02/02/2026. So now let's walk through the most significant changes. So we have a incorporation by reference, which means that the FDA is now incorporating the ISO thirteen and forty five by reference into its 21 CFR Part A20, meaning that the ISO standard is now part of The US federal law. Compliance with ISO 3,040 five-twenty six is compliance with the FDA's regulation. The FDA retains authority to add additional requirements, but the baseline remains the ISO three and forty five. Why this matters really is that manufacturers already ISO 3,045 certified can immediately meet harmonized requirements and those that are still operating only under the legacy 21 CFR part A20 and have not yet implemented the ISO must update their systems. While the 21 CFR part A20 had elements of risk based thinking, certainly the ISO 24,005 makes it central to the entire quality management system. Identify risks to product quality, safety and performance, take action to address risks, evaluate effectiveness of actions, continuously improve. So what should you expect an FDA inspections under a QMSR? Inspectors certainly will ask something like, how does your process reflect the risk based approach? What's your rationale for this specific control that you've chosen? Or how do you monitor whether your control of your process is effective? Our recommendation manufacturers is to revisit all of ISO's and QMISR relevant processes and to ask yourself, what are the process related risks? Did we consider all reasonably expectable process risks that may have a direct or indirect impact on the device safety and performance? Did we implement the process in a way to sufficiently address these risks? If the answer is yes, that's great. If the answer, however, is no, perform a gap analysis to understand which processes related risks are open and must be covered. Depending on their impact on the processes effectiveness and the device safety performance, the implementation of appropriate control measures in their respective process may be time critical and may not wait for the next regular process update. One of the most visible changes certainly is terminology. The medical device file, MDF, according to ISO 3,045, has a broader scope than the former DMR, device master record idea, and includes design, manufacture and post market info. Ergo, design history is integrated into the overall device file and so is the production history, which is now also a part of the comprehensive file. So what does this mean in practice? You don't just rename folders and files. The MDF concept requires a more integrated approach to documentation instead of three separate systems, DMR, DHF, DHR. The ISO thirteen forty five views these as components of one comprehensive medical device file that tells the complete story of the device from conception through retirement. What you should do now is to audit your current documentation structure to identify what constitutes your medical device file under the new framework and to ensure all stakeholders design, manufacturing, quality, regulatory, understand the integrated approach. The ISO 3,045 places significantly more emphasis on management accountability and employee competency. The legacy 21CFR Part A20 requires personnel to be trained to adequately perform their roles and documentation of training needs. ISO thirteen forty five clause 6.2 goes further by explicitly requiring documented evidence of competency and evaluation of training effectiveness, making competency assessment a formal, auditable requirement rather than an implicit expectation. So what you should do is ensure that competency requirements for each role actually exist and are documented to develop competency assessment methods, test certifications on the job assessment, for example, are typical methods, to ensure evidence of competency in personnel files, and to establish a schedule for competency verification, example, annual or per SOP. Last but not least, you should ensure senior leadership actively reviews and knows quality management system performance in the management reviews. So one of the most notable changes certainly is that the ISO 3,045 integrates the risk management system as a requirement and references to ISO 4,971 and clause 7.1. So the risk management now is embedded in each phase. Design controls explicitly reference to the ISO four thousand nine seventy one, which means that design decisions must be justified by risk analysis, residual risk is evaluated and documented. While this risk consideration throughout design controls was implicitly required in the legacy QSR, particularly through intended use and user needs, the ISO 3,045 clause seven one makes this explicit and formally traceable to ISO 14,971. Under the new humans RFDA incorporates by reference the ISO 3,045, so supply controls must meet the ISO's requirements for purchasing and outsource processes. You should refer to classes 4.1.5 or 4.1.6 and 7.4 for these topics. And generally speaking, there's no major difference in the expected level of controls. However, what's different is that evaluation must be documented and risk based. Monitoring and rehabilitation are explicitly stated requirements. Supply agreements must address quality requirements. And what you should really do to check if you're, you know, and conformity with these expectations is to ensure your supply management system is risk based. Coming back to the risk based approach, including your supplier categories and qualification, as well as the requalification criteria. If necessary, assess current suppliers using ISO 3,040 criteria, update supplier agreements to reflect quality requirements if needed, implement key performance indicators for supply monitoring if you haven't already, and schedule regular supplier reevaluation, typically annual. So for organizations that haven't yet fully transitioned, here's a practical implementation roadmap with four phases, obviously. Phase one, the assessment, audit your current quantum management system against the ISO 3,045, identify gaps in your documentation, your procedures and competencies, prioritise changes by risk, criticality and impact to then make an estimate resource requirement. The second phase then is the documentation update where you would revise the quality manual where necessary, update your procedures as required, and particularly for management responsibility, design controls, fire management, update training and competency processes, revise the inspection readiness documents. And then the third phase is system implementation, meaning that you implement the changes in your quality management system, and also if you're using quality management system software, and also train relevant personnel on new or changed procedures and competencies, pilot key processes, for example, the supplier evaluation or design review, conduct internal audits against the new or changed procedures, and the fourth phase, make sure you verify your changes and you're ready by conducting a management review of your updated quality management system, perform a gap audit or mock FDA inspection, finalize inspection readiness, establish ongoing monitoring of compliance. And since we're already at the March and February 2 was the end of the transition date, organizations should maybe prioritize phases two through four ensuring readiness for FDA inspections under the new framework. You may have heard of the proposed EU MDR IVDR changes. And I want to talk to you about some of these changes and what they may mean to you and how you should handle them. So on 12/16/2025, the European Commission unveiled a comprehensive proposal to amend both the EU MDR and the EU IVDR. So let me give you a little context here. The MDR and IVDR have been in effect since 2017 or 2022 respectively. While both aimed at strengthening the European regulatory oversight and patient safety, they also create a significant administrative burden, particularly for SMEs, the small and medium sized enterprises. The Commission's objective now is to simplify rules, reduce administrative burden, improve predictability, and support innovation and competitiveness while maintaining a high level of patient safety and public health protection. This is a careful balance. These are not drawbacks. They are refinements based on real world implementation experience. So before we get to some of the proposed changes, let me explain why 2026 is a critical moment. First of all, we have a simplification and proportionality. The Commission's proposal resets the system to work proportionate oversight, lighter touch for genuinely lower risk technologies, while keeping stringent controls where risk is higher. So expect clearer roads for well established technologies and some targeted down classification, for example, certain software, reusable instruments. So we spend effort where it matters most for patients. Second, the reduction of administrative burden, which basically means to bring reporting documentation back to essentials. Fewer redundant reports, more risk based frequencies and clearer change control categories. So routine updates don't trigger full reviews. The aim here is to free capacity without lowering safety bar. Regarding number three, the innovation and availability of devices for special patient groups or situations, the proposal explicitly tackles availability, especially for niche or breakthrough technologies and special use cases. Alongside simplifications, stakeholders expect faster, clearer pathways, so innovations for small populations of critical situations don't stall. With regards to the fourth change, predictability and cost efficiency of certification, this is a core objective. Risk periodic reviews in place of a rigid five year expiry and more explicit expectations for evidence. This should reduce recertification and focus, notified body time where risk justifies it, cutting time and cost without trading off on safety. Furthermore, the coordination within the decentralized system, of changing the EU's decentralized model, the proposal tightens coordination, a stronger link between MVCGMED and the MVCG and EMA support for expert panels and for authorities on borderline classification and vigilance issues. The goal really is to have consistent decisions across member states. With regards to the sixth topic, further digitalization, this is a lever to remove friction. Friction. Think more efficient data flows and better use of EU systems, for example, Unimate, which we've heard earlier, to reduce duplication and speed up oversight. The evaluation behind the proposal explicitly calls out digital tooling to cut burden. Regarding the international cooperation, the intent of the commission is to frame these changes in competitiveness terms, meaning that keeping Europe attractive versus other jurisdictions, better predictability and proportionate rules are also about global alignment and avoiding regulatory drag that pushes launches elsewhere. Then we have last but not least the interplay with other union legislation, meaning that this package is designed to mesh with other new frameworks. Pharma reforms that are coming up, the Biotech Act, the SOHO regulation, the references to the AIX certainly. So device IBD, medicinal and combined studies aren't managed in silos. The intention here is to have more consistent cross regulatory pathways. Looking at the scenarios here, the experience with the current regulation, the EU MDR and IVDR teaches us that we should have some patients with the final ruling and publication of these proposals provided that they will be unanimously agreed with and no changes are required. If we look at the optimistic scenario here, the agreement to be reached in 2026, then if that is the case, a publication in the official journal may be expected in late twenty twenty six, early twenty twenty seven maybe. This really requires a high priority, minimal opposition and little political friction. The more realistic scenarios that probably will reach an agreement by early twenty twenty seven or mid twenty twenty seven, which will then mean publication of the OJ sometime in 2027, assuming obviously that the usual political friction and limited opposition appear. A more conservative estimate then is obviously an agreement sometime by 2028 publication in the OJVN '28 or even '29, which is when it's subject to significant political friction, which is not very unlikely to happen, numerous conflicting factors and potential arbitration proceedings. What you see here is a comparison between the current regulation and proposed changes with regards to article sixty one point four and sixty one point five. So on the left hand side is the current regulation or the current requirements. When we look at proposed changes, what we see here with regards to clinical investigations and for which classes these are mandatory is that we have in addition from so far implantable devices and class three devices to implantable class 2B and class three devices, so we have two class 2B added here. Another change with regards to article 61.5 is that manufacturer of device demonstrated to be equivalent to an already marketed device not manufactured by it may also rely on paragraph four in order not to perform a clinical investigation provided that the original clinical evaluation has been performed in compliance with the requirements of this regulation and the manufacturer provides clear evidence thereof to the notified body. What does this mean? Looking at the practical significance here of this specific proposal is that the practically unattainable requirement that we had so far, which meant having a contract in place and ongoing full access to technical documentation will no longer be required if this change goes through. Equivalence with third party products could become a realistic possibility. At the same time, the following remains true for implantable class two, class three devices. Clinical trials are generally required. An exception applies only if the criteria of ARDIC-six 14 are met, including equivalence based on Annex 14 logic and notified body review. This is certainly an expected shift, so the discussion is shifting from access to technical documentation to quality and robustness of the evidence that you provide, plus proof that the original clinical evaluation complies with the EU MDR, which means clear evidence. With this proposal, the Commission aims to achieve, among other things, simplification, proportionality and greater predictability, particularly with regard to clinical evidence and equivalence. Bring in some context here, if you remember the MDCG twenty twenty three-seven describes the exemptions from the investigation requirements under Article 61.4 through six. And it explicitly addresses which data are necessary for equivalence, not legally binding, but it's relevant in practice, the MCG guidance document. This proposal that we're looking at, however, leaves us with some new questions like what exactly does clear evidence mean? Which artifacts will the North Red bodies expect as proof that the clinical evaluation of the equivalent product complies with the EU MDR? How will sufficient access be assessed in future if no contract exists? Will the notified body in practice only accept the exception if a robust PMCF plan, including studies, addresses residual uncertainties? While we have some clarification or simplification, there are new questions by using certain terminologies like clear evidence. Another example that I wanted to point out is the requirement to justify the use of single use products. There have been amendments to Article 17. Again, the practical significance of the proposal is that single use becomes a claim that requires justification based on design and risk management rationale, not just labeling convention, So you should expect more focus on technical or risk based justification for why safe reprocessing is not possible or why GSPRs could not be met upon reuse. To give some context again, is that the Commission's report on Article 17 shows fragmentation, low Notified Body certification, and a very low market penetration rate, So the system has only worked to a limited extent so far, which brings us to the conclusion that the reform goals equal clarity and practical ability and less of a dead letter reprocessing regime. Again, we're left with new questions such as what evidence is sufficient to justify a single use claim, example, material degradation, capability, functional drift, residue risk. How much will this harmonize? Will this be harmonized across product groups versus case by case? And again, transition periods from when does the justification requirement effectively apply in technical documentation and labeling. While there are some very interesting changes proposed in this proposal by the commission, our message is stay ready, but stay calm and stay compliant. No premature rewrites are required at this point. Follow the process, but don't do anything rash. This concludes the overview of the Q1 twenty twenty six regulatory updates. You can find additional material on our websites by scanning the QR codes that you find here. We have guidance on tech file factory. We have information material on clinical affairs services that we offer or the international regulatory compliance services that we offer throughout NSF's life science divisions. Furthermore, you can check out our website on upcoming keynotes via this link or the QR code and feel free to reach out to myself or the general website, our LinkedIn channel or our general info email if you want to reach out to me or my colleagues and have specific questions. Thank you very much. This concludes the quarterly review of some of the most significant regulatory updates. Should you have any questions again, please feel free to use the Q and A function here or contact me directly by email and stay healthy, stay safe. Goodbye.